17 completed, 4 terminated, 2 active not recruiting, 2 recruiting. 27 Phase 2, 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 27 | Completed 17, Terminated 4, Active not recruiting 2, Recruiting 2, Unknown 1, Withdrawn 1 |
| Phase 1 | 8 | Completed 5, Terminated 2, Withdrawn 1 |
Follow belinostat: new trials by email Literature Review of belinostat trials Research Report on belinostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity Belinostat, Cisplatin, Etoposide - Carcinoma, Neuroendocrine, Tumor, Neuroendocrine | Phase 2 | Recruiting | National Cancer Institute (NCI) | 60 | 2026-11-03 | 2026-10-29 |
| Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma Binimetinib, Belinostat - Metastatic Uveal Melanoma | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 7 | 2021-12-15 | 2026-04-06 |
| Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL Azacytidine, Romidepsin, Belinostat - PTCL | Phase 2 | Recruiting | University of Virginia | 50 | 2021-02-19 | 2026-01-21 |
| Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma Belinostat, Biopsy Procedure, Biospecimen Collection - Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 19 | 2020-09-08 | 2026-09-08 |
| Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma Belinostat, Zidovudine, Interferon-Alfa-2b - Adult T-cell Leukemia-Lymphoma, ATLL | Phase 2 | Completed | University of Miami | 15 | 2016-12-12 | 2026-03-10 |
| Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma Busulfan, Caphosol, Glutamine - Lymphoma | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2016-06-01 | 2016-05-04 | |
| MRSI to Predict Response to RT/TMZ ± Belinostat in GBM Standard Radiation Therapy, Standard Temozolomide, Belinostat - Glioblastoma Multiforme of Brain | Phase 2 | Unknown | Emory University | 29 | 2014-05-07 | 2023-05-06 |
| Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL belinostat, rituximab, yttrium Y 90 ibritumomab tiuxetan - Anaplastic Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 2 | Completed | University of Arizona | 5 | 2012-08-31 | 2018-08-28 |
| MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC Belinostat, Carboplatin, Paclitaxel - Stage IV Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Acrotech Biopharma Inc. | 23 | 2010-12-01 | 2020-01-06 |
| A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer Belinostat and Erlotinib - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Herlev Hospital | 5 | 2010-10-01 | 2020-10-19 |
| Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer Belinostat, carboplatin, paclitaxel and bevacizumab - Non-Small-Cell Lung Carcinoma | Phase 1 / Phase 2 | Terminated | Holy Cross Hospital, Florida | 7 | 2010-04-01 | 2018-02-23 |
| Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin belinostat, carboplatin - Brenner Tumor, Fallopian Tube Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 29 | 2009-12-01 | 2019-07-23 |
| Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary belinostat, carboplatin, paclitaxel, carboplatin, paclitaxel - Carcinoma of Unknown Primary | Phase 2 | Completed | Valerio Therapeutics | 89 | 2009-02-01 | 2015-07-28 |
| Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Belinostat - Peripheral T-cell Lymphoma | Phase 2 | Completed | Spectrum Pharmaceuticals, Inc | 129 | 2008-12-15 | 2021-10-29 |
| Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage Belinostat (PDX101) - Thymoma, Thymic Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 41 | 2007-12-01 | 2015-09-30 |
| Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy PXD101, idarubicin - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Valerio Therapeutics | 41 | 2007-08-01 | 2015-07-28 |
| A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma PXD101 - Multiple Myeloma | Phase 2 | Terminated | Valerio Therapeutics | 4 | 2007-03-01 | 2015-07-08 |
| A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas PXD101, Doxorubicin - Dose Escalation: Solid Tumors, MTD: Soft Tissue Sarcomas | Phase 1 / Phase 2 | Completed | Valerio Therapeutics | 41 | 2006-12-01 | 2015-07-28 |
| Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors Belinostat, Laboratory Biomarker Analysis - Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 32 | 2006-09-01 | 2018-08-20 |
| PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery belinostat, laboratory biomarker analysis - Advanced Malignant Mesothelioma, Epithelial Mesothelioma | Phase 2 | Completed | National Cancer Institute (NCI) | 13 | 2006-06-01 | 2018-06-07 |
Showing 20 of 27. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (3) · Fallopian Tube Neoplasms (3) · Carcinoma, Ovarian Epithelial (2) · Leukemia, Myeloid, Acute (2) · Lung Neoplasms (2) · Lymphoma (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, T-Cell, Peripheral (2) · Multiple Myeloma (2) · Ovarian Neoplasms (2) · Adenocarcinoma (1) · Bone Marrow Neoplasms (1) · Brenner Tumor (1) · Burkitt Lymphoma (1) · Carcinoma, Hepatocellular (1)
National Cancer Institute (NCI) (10) · Valerio Therapeutics (7) · Acrotech Biopharma Inc. (1) · Emory University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Herlev Hospital (1) · Holy Cross Hospital, Florida (1) · M.D. Anderson Cancer Center (1) · Spectrum Pharmaceuticals, Inc (1) · University of Arizona (1) · University of Miami (1) · University of Virginia (1)
United States (22) · Denmark (6) · United Kingdom (5) · France (4) · Germany (4) · Canada (2) · Israel (2) · Belgium (1) · Croatia (1) · Hungary (1) · Italy (1) · Netherlands (1) · Norway (1) · Poland (1) · Russia (1)
Adam Lerner, MD (1) · Ahmad Tarhini, MD, PhD (1) · Amanda Cashen (1) · Amanda Cashen, MD (1) · Amit Oza (1) · Andreas Neubauer, MD (1) · Andreas Viardot, MD (1) · Andrei Shustov, MD (1) · Beata Holkova, MD (1) · Bernard Poiesz, MD (1) · Brian Matthews, MD (1) · Charles Farber, MD (1)
PMID 21502553, PMID 23382909, PMID 24369094, PMID 25404094, PMID 25962426, PMID 26921086, PMID 28869931, PMID 34552007, PMID 40932107
N01CM62205 (2), N01CM62209 (2), 2008 (1), F30CA206291 (1), N01CM17107 (1), N01CM62203 (1), P30CA015083 (1), P30CA023074 (1), P30CA138292 (1), R21NS100244 (1), U01CA172027 (1), U10CA027469 (1), U10CA032102 (1), UM1CA186686 (1)